Imidazoline Receptor System: The Past, the Present, and the Future

咪唑啉受体 胍丁胺 莫索尼定 利门尼丁 可乐定 受体 兴奋剂 化学 药理学 立体化学 生物化学 内分泌学 医学 氨基酸 精氨酸
作者
Pascal Bousquet,Alan L. Hudson,Jesús A. Garcı́a-Sevilla,Jun‐Xu Li
出处
期刊:Pharmacological Reviews [American Society for Pharmacology & Experimental Therapeutics]
卷期号:72 (1): 50-79 被引量:88
标识
DOI:10.1124/pr.118.016311
摘要

Imidazoline receptors historically referred to a family of nonadrenergic binding sites that recognize compounds with an imidazoline moiety, although this has proven to be an oversimplification. For example, none of the proposed endogenous ligands for imidazoline receptors contain an imidazoline moiety but they are diverse in their chemical structure. Three receptor subtypes (I1, I2, and I3) have been proposed and the understanding of each has seen differing progress over the decades. I1 receptors partially mediate the central hypotensive effects of clonidine-like drugs. Moxonidine and rilmenidine have better therapeutic profiles (fewer side effects) than clonidine as antihypertensive drugs, thought to be due to their higher I1/α2-adrenoceptor selectivity. Newer I1 receptor agonists such as LNP599 [3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine hydrochloride] have little to no activity on α2-adrenoceptors and demonstrate promising therapeutic potential for hypertension and metabolic syndrome. I2 receptors associate with several distinct proteins, but the identities of these proteins remain elusive. I2 receptor agonists have demonstrated various centrally mediated effects including antinociception and neuroprotection. A new I2 receptor agonist, CR4056 [2-phenyl-6-(1H-imidazol-1yl) quinazoline], demonstrated clear analgesic activity in a recently completed phase II clinical trial and holds great promise as a novel I2 receptor–based first-in-class nonopioid analgesic. The understanding of I3 receptors is relatively limited. Existing data suggest that I3 receptors may represent a binding site at the Kir6.2-subtype ATP-sensitive potassium channels in pancreatic β-cells and may be involved in insulin secretion. Despite the elusive nature of their molecular identities, recent progress on drug discovery targeting imidazoline receptors (I1 and I2) demonstrates the exciting potential of these compounds to elicit neuroprotection and to treat various disorders such as hypertension, metabolic syndrome, and chronic pain.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沿途有你完成签到 ,获得积分10
8秒前
范玉平完成签到,获得积分10
9秒前
甜甜的问芙完成签到 ,获得积分10
11秒前
hua完成签到 ,获得积分10
18秒前
reset完成签到 ,获得积分10
21秒前
潇洒的书文完成签到,获得积分10
24秒前
畅快的谷秋完成签到 ,获得积分10
24秒前
Jonsnow完成签到 ,获得积分10
27秒前
38秒前
咯咯咯发布了新的文献求助10
42秒前
玩命的无春完成签到 ,获得积分10
44秒前
maclogos完成签到,获得积分10
49秒前
蓝桉完成签到 ,获得积分10
1分钟前
isedu完成签到,获得积分10
1分钟前
Tonald Yang发布了新的文献求助10
1分钟前
seacnli完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
HJBF666完成签到 ,获得积分10
2分钟前
Tonald Yang发布了新的文献求助10
2分钟前
2分钟前
powwwop完成签到,获得积分20
2分钟前
powwwop发布了新的文献求助10
2分钟前
打鬼忍者完成签到 ,获得积分10
2分钟前
anran完成签到 ,获得积分10
2分钟前
风落完成签到 ,获得积分10
2分钟前
wwe完成签到,获得积分10
2分钟前
IngridX完成签到 ,获得积分10
2分钟前
简单的笑蓝完成签到 ,获得积分10
2分钟前
loren313完成签到,获得积分0
3分钟前
平常从蓉完成签到,获得积分10
3分钟前
漂亮夏兰完成签到 ,获得积分10
3分钟前
netyouxiang完成签到,获得积分10
3分钟前
轻松元绿完成签到 ,获得积分10
3分钟前
俊逸的白梦完成签到 ,获得积分10
3分钟前
迷你的夜天完成签到 ,获得积分10
3分钟前
共享精神应助摆渡人采纳,获得10
3分钟前
犹豫芝麻应助DDS采纳,获得10
3分钟前
kbcbwb2002完成签到,获得积分10
3分钟前
zhangbh1990完成签到 ,获得积分10
3分钟前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162359
求助须知:如何正确求助?哪些是违规求助? 2813350
关于积分的说明 7899783
捐赠科研通 2472848
什么是DOI,文献DOI怎么找? 1316556
科研通“疑难数据库(出版商)”最低求助积分说明 631375
版权声明 602142